Ocular Pharmacology High-Yield: Drugs, Doses and Side Effects Tables

Ocular pharmacology MCQs are easier when you stop treating them as a list of bottles. Build each answer from five things: class, target, ocular effect, systemic consequence and one classic trap. A dose belongs to a specific product, indication, route, patient and current label; this is therefore an exam-revision guide, not a prescribing chart. For any real prescription or practical-viva dose question, verify the current individual monograph and local protocol.

The answer pattern that survives a difficult SBA

Start with the noun in the stem. “Asthma”, “bradycardia”, “darkened iris”, “anterior uveitis”, “dendritic lesion” and “perioperative miosis” are usually more useful than a half-remembered brand name. Then run this sequence:

1. Name the pharmacological class.
2. State the target or dominant mechanism.
3. Predict the ocular effect.
4. Look for the adverse effect or contraindication that fits the patient.
5. Check whether the question is really testing route, formulation, preservative, timing or an interaction.

That order matters. “Reduces IOP” alone is a weak answer because several classes do that. “Reduces aqueous production via beta blockade; therefore systemic bronchospasm and bradycardia are relevant distractors” is an answer you can defend in an MCQ and a viva.

A safe way to handle dose questions

In an examination, first identify whether the examiner wants a familiar labelled regimen, an emergency sequence, a route, or simply the fact that a drug is topical versus intracameral, periocular, systemic or intravitreal. Do not transfer one preparation’s concentration or frequency to another. Strength, age limits, renal function, pregnancy, corneal integrity, indication, concomitant drugs and country-specific product information can all change the appropriate answer.

For current prescribing information, use the individual product’s official label, such as the searchable DailyMed database, and the applicable formulary such as the BNF. In a practical examination, it is sound to say: “I would confirm the current formulation and dose from the authorised product information and local policy.” That is safer and more accurate than reciting an orphaned dose table from an old note.

The five-field drug card

Use one index card per class. The front is the trigger; the back is the explanation.

Reverse the cards. See “conjunctival allergy and dry mouth” and ask for alpha-2 agonism. See “mydriasis without cycloplegia” and ask for a sympathomimetic rather than an antimuscarinic. This reverse direction is where many single-best-answer questions live.

IOP-lowering drugs: learn production versus outflow first

The high-yield distinction is whether the class mainly suppresses aqueous production or improves outflow. A useful overview of open-angle glaucoma pharmacology and its classes is available in the NCBI Bookshelf review of open-angle glaucoma. It is background for revision, not a substitute for current labels.

Beta-blockers

For a beta-blocker stem, ask what systemic beta blockade would do. A patient with reactive airways disease, marked bradycardia, heart block or concomitant rate-limiting therapy should make you pause in an exam question. The distractor often states a correct ocular effect but ignores the systemic contraindication. Punctal occlusion may reduce systemic absorption in teaching discussions, but never turn that fact into a claim that it removes risk.

Prostaglandin analogues

The exam association is increased uveoscleral outflow. The recognisable cosmetic-adjacent effects—hypertrichosis, periocular skin darkening and heterochromia—are high-yield because they reveal the class without naming it. Be precise: not every patient develops them, and exact counselling or use decisions need the current individual product information.

Carbonic anhydrase inhibitors

The useful comparison is route-specific. A topical inhibitor is a local aqueous suppressant, whereas systemic carbonic anhydrase inhibition carries a different practical adverse-effect and interaction burden. If a stem contains paraesthesia, altered taste, acid–base language, renal history or sulfonamide-related caution, it is asking you to think beyond a drop. Do not overstate a class cross-reactivity rule; labels and local guidance control real decisions.

Alpha-2 agonists and miotics

Alpha-2 agonist questions commonly hinge on allergy, fatigue or dry mouth. A miotic question commonly hinges on pupil constriction, ciliary muscle effects, brow ache or reduced vision in low illumination. A clean viva sentence is: “This class increases trabecular outflow through ciliary-muscle contraction, but the pupil and accommodation effects explain its characteristic symptoms.”

Combination drops and preservatives

Combination products are a favourite source of avoidable errors. Identify both active classes, then check whether the question is about additive IOP lowering, duplicated therapy, preservative intolerance or systemic suitability. “Once daily” and “fixed combination” are not mechanisms. Do not infer the contents of a product from its brand name; read the generic components in the stem.

Pupil pharmacology: receptor logic beats memorising pairs

The iris sphincter is parasympathetically driven; the dilator is sympathetically driven. The ciliary muscle gives the extra clue.

Antimuscarinics and cycloplegics

For atropine-like, cyclopentolate-like or tropicamide-like questions, describe blockade of muscarinic activity at the sphincter and ciliary muscle. The duration differs markedly between agents and preparations; do not use a generic “cycloplegic dose” as a shortcut. In a child, an elderly patient, or a susceptible patient with a relevant systemic history, the adverse-effect discussion must be especially cautious and product-specific.

Sympathomimetics

Phenylephrine-type questions test alpha-1-mediated dilator contraction. The single best discriminator from antimuscarinic dilation is absent cycloplegia. If the question shifts to cardiovascular adverse effects, route, concentration and patient factors become central. State the mechanism first; then say that dose and suitability must be verified from the current monograph.

Miotics

Pilocarpine-type stems often ask why the patient reports brow ache or myopic shift: ciliary-muscle contraction supplies the explanation. Do not reduce the class to “used in glaucoma.” The question may instead test pharmacological reversal of dilation, angle anatomy, accommodation or a contraindication in a specific clinical context.

Anti-inflammatory drugs: mechanism, monitoring and mimicry

The exam-safe frame is not “give steroid for red eye.” It is: identify the inflammatory setting, distinguish infective risk from sterile inflammation, and know the monitoring problem that follows a drug class.

Topical corticosteroids

“Steroid responder” is an exam phrase, not a diagnosis to apply casually. The core association is elevated IOP with corticosteroid exposure in susceptible people, alongside cataract, delayed epithelial healing and a risk of worsening or obscuring infection. A good answer names the class effect and says that choice, regimen and monitoring depend on the indication and current guidance. It does not give a universal taper.

NSAIDs

Ophthalmic NSAID questions are often constructed to see whether you call every anti-inflammatory drug a corticosteroid. Keep mechanism distinct. Corneal surface vulnerability, epithelial defects and concomitant treatment can change risk. In an OSCE or viva, say that use must be indication-specific and guided by the current product information; that is clinical discipline, not evasiveness.

Antimicrobials and antivirals: match the organism class, not the colour of the eye

An antibacterial, antiviral and antifungal are not interchangeable “infection drops.” Start with the presumed organism category and the tissue involved. Then ask whether the stem wants mechanism, resistance, epithelial toxicity, renal/systemic considerations, contact-lens context or a characteristic corneal pattern.

The clinical management of keratitis is outside this article’s remit. For exam purposes, describe the class and the reason an organism-specific diagnosis, specimen strategy and senior/local protocol matter. Do not convert a recall point into patient-specific treatment advice.

Retina, anaesthesia and perioperative pharmacology

Retinal pharmacology is often tested through route and mechanism. Intravitreal anti-VEGF agents target the VEGF pathway; agents and indications are not interchangeable across every retinal disease, and risks, consent and follow-up are protocol-dependent. The correct exam habit is to state molecule class, target, route and the important ocular adverse-event category without pretending that a revision table can supply a live injection protocol.

Local anaesthetic questions reward anatomy plus toxicity awareness. Know the difference between surface anaesthesia, regional block concepts and systemic local-anaesthetic toxicity recognition. For intracameral or perioperative agents, identify the surgical purpose, route and formulation; never transpose a topical bottle concentration into an intraocular-use answer.

Mydriatics, miotics, viscoelastics, antibiotics and anti-inflammatory agents may appear together in a cataract surgery viva. Sort them by purpose: pupil, pain/sensation, inflammation, infection prevention, IOP or tissue protection. That is more robust than rehearsing a fixed theatre list.

Ten high-yield traps to practise

1. A topical beta-blocker can still produce clinically relevant systemic beta blockade.
2. Prostaglandin analogues increase uveoscleral outflow; they are not aqueous suppressants.
3. Alpha-2 agonism and alpha-1-mediated dilation are different questions.
4. Mydriasis with cycloplegia points towards antimuscarinic action; mydriasis alone points elsewhere.
5. A steroid can improve inflammatory signs while increasing IOP or obscuring infection risk.
6. Route changes the adverse-effect profile. Do not mix topical and systemic carbonic anhydrase inhibitor facts.
7. A fixed combination contains two mechanisms; inspect both before choosing an answer.
8. A product’s dose cannot be inferred from its class name.
9. “Current guideline” is not evidence unless the source and date are identified.
10. In a clinical vignette, the safest exam answer may be to obtain the relevant information and follow local/authorised guidance, rather than invent certainty.

A 30-minute revision loop

Use five minutes to review one mechanism grid, ten minutes for mixed reverse cards, ten minutes for timed MCQs and five minutes for error coding. Code every wrong answer as one of four failures: mechanism, route, adverse effect or wording. The next day, make a card only for the failed link. This prevents a 30-page drug list from becoming passive highlighting.

For practical recall, organise cards by station prompt: “identify this bottle,” “state mechanism,” “mention two adverse effects,” “what would you verify before use?” That format also makes a viva answer safer. The Ophthalmology Drugs Practical PDF and Instruments & Drugs for Practical Exams/Viva are on-site revision routes when you want practical-focused material; practise the mechanisms first, then check the exact current reference required by your examination.

Sources

• DailyMed: National Library of Medicine drug-label database — use the individual, current product label for formulation, indication, contraindications and dose information.
• BNF — current UK formulary; consult the individual monograph.
• NCBI Bookshelf: Open Angle Glaucoma — aqueous dynamics and IOP-lowering class context.
• American Academy of Ophthalmology, Basic and Clinical Science Course: Fundamentals and Principles of Ophthalmology and Glaucoma — standard exam-reference context; use the current edition available to your programme.